Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
NCT03467867Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Apr 2018
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, rituximab + hyaluronidase human in chronic lymphocytic leukemia (CLL), sponsored by Georgetown University. Started Apr 2018; status: active, not recruiting.
02
Drugs
venetoclaxrituximab + hyaluronidase human
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03467867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467867.